Business Wire

Thales Launches Europe’s First Certified Smartcard Ready for the Quantum Age

7.10.2025 08:00:00 CEST | Business Wire | Press Release

Share

As quantum computing evolves, many of today’s cryptographic methods will no longer be secure, since quantum computers will be able to solve complex mathematical problems much faster than classical computers. A recent Gartner® report* says “By 2029, advances in quantum computing will make conventional asymmetric cryptography unsafe to use.” Thales has spent years investing in post-quantum cryptography to ensure critical systems stay safe in the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006066043/en/

© Sanna Liimatainen - Thales

By becoming the first company worldwide to receive high-level Common Criteria1 certification for a quantum-resistant smartcard, Thales will help government services protect sensitive data—such as those on ID cards, health cards, and driver’s licenses—and ensure that citizens’ identities are secure against emerging quantum threats.

The innovative smartcard (‘MultiApp 5.2 Premium PQC’), developed by Thales and certified by the French Cybersecurity Agency (Agence nationale de la sécurité des systèmes d’information – ANSSI), uses advanced digital signature designed to resist attacks, even from powerful quantum machines. It’s the first of its kind to be certified at such a high security level (EAL 6+2) under the Common Criteria framework. The certified product also features new Digital Signature Algorithms3 standardised by the American NIST - National Institute of Standards and Technology. These specific signature algorithms are powerful cryptographic tools used to verify that data or a digital message really comes from the right sender and has not been altered.

From an end-user perspective, nothing changes: citizens will continue to use their cards as usual. What’s revolutionary is what’s inside. The card uses a new generation cryptographic signature designed to withstand the immense computing power of tomorrow’s quantum computers. This ensures that sensitive personal data remains protected not just today—but well into the future.

"This first certification for a solution incorporating post-quantum cryptography reflects ANSSI’s commitment to supporting innovation, while upholding the highest cybersecurity standards. The joint work of Thales, CEA-Leti ITSecurity Evaluation Facility, and ANSSI is a strong signal that Europe is ready to lead the way in post-quantum security, enabling organisations and governments to deploy solutions that anticipate future risks, rather than waiting for quantum computers to become mainstream."Franck Sadmi, Head ofNational Certification Center,French Cybersecurity Agency (ANSSI).

"This certification is a landmark moment not only for Thales but for the entire digital security ecosystem. It shows that future-proof cybersecurity is no longer a concept—it's a reality. By achieving the highest level of security for a quantum-resistant smartcard, Thales is paving the way for trust in tomorrow’s civil identities. We’re proud to lead this crucial transformation."Nathalie Gosset, VP Identity & Biometric Solutions at Thales.

1 An international standard confirming the product meets strict security requirements.

2 The Evaluation Assurance Level (EAL) is an international scale used to measure the robustness of IT security. It ranges from EAL1 (basic tested) up to EAL7 (the highest, formally verified level). An EAL6+ certification means the product has been tested and proven to provide very high security against sophisticated attacks, suitable for critical applications like government, finance, and defense.

3 FIPS 204 is a new U.S. government standard that defines a digital signature algorithm designed to remain secure even in the age of quantum computers. It is a foundation for digital integrity of things like secure transactions, ID documents, software updates, or electronic contracts. FIPS standards are published and approved by NIST (the U.S. National Institute of Standards and Technology) and are widely recommended and adopted across industries worldwide, especially in sectors like government, defense, finance, and digital technology.

* Gartner®, Postquantum Cryptography: The Time to Prepare Is Now!, Mark Horvath et al., 1 July 2024

The Gartner content described herein (the “Gartner Content”) represents research opinion or viewpoints published, as part of a syndicated subscription service, by Gartner, Inc. ("Gartner"), and is not a representation of fact. Gartner Content speaks as of its original publication date (and not as of the date of this PR), and the opinions expressed in the Gartner Content are subject to change without notice.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT
Thales Group
Download HD photos

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006066043/en/

Contacts

PRESS CONTACT
Thales, Media Relations CYBER & DIGITAL
Vanessa Viala – vanessa.viala@thalesgroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye